Pfizer Inc.'s Back-Pain Medication Meets Primary Phase 3 Goals

Published: Jan 23, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Pfizer Inc. (PFE: Quote) reported top-line results of Phase 3 trial of investigational agent ALO-02 in patients with moderate-to-severe chronic low back pain. During this study, ALO-02 met the primary efficacy endpoint, showing a statistically significant difference from placebo.

Help employers find you! Check out all the jobs and post your resume.

Back to news